OBJECTIVE: To assess, among women with HIV, whether long-term oral Lactobacillus rhamnosus GR-1 and Lactobacillusreuteri RC-14 supplementation can prevent bacterial vaginosis (BV) and enhance the cure rate of metronidazole among those with BV. METHODS: A randomized, double-blind, placebo-controlled trial conducted among 65 HIV-infected women with an aberrant microbiota (Nugent score 4-10) who were randomized to receive daily probiotics or placebo for 6 months. Those with BV (Nugent score 7-10) additionally received metronidazole for 10 days (400 mg twice daily). RESULTS: We did not find an enhanced cure rate of BV among women with HIV treated with adjuvant probiotics tometronidazole treatment. Among women with an intermediate vaginal flora, probiotics tended to increase the probability of a normal vaginal flora (odds ratio 2.4; P=0.1) and significantly increased the probability of a beneficial vaginal pH (odds ratio 3.8; P=0.02) at follow-up. CONCLUSION: Supplementation of probiotic L. rhamnosus GR-1 andL. reuteriRC-14 did not enhance the cure of BV among women living with HIV, but may prevent the condition among this population. TRIAL REGISTRATION: NCT00536848.
RCT Entities:
OBJECTIVE: To assess, among women with HIV, whether long-term oral Lactobacillus rhamnosus GR-1 and Lactobacillus reuteriRC-14 supplementation can prevent bacterial vaginosis (BV) and enhance the cure rate of metronidazole among those with BV. METHODS: A randomized, double-blind, placebo-controlled trial conducted among 65 HIV-infectedwomen with an aberrant microbiota (Nugent score 4-10) who were randomized to receive daily probiotics or placebo for 6 months. Those with BV (Nugent score 7-10) additionally received metronidazole for 10 days (400 mg twice daily). RESULTS: We did not find an enhanced cure rate of BV among women with HIV treated with adjuvant probiotics to metronidazole treatment. Among women with an intermediate vaginal flora, probiotics tended to increase the probability of a normal vaginal flora (odds ratio 2.4; P=0.1) and significantly increased the probability of a beneficial vaginal pH (odds ratio 3.8; P=0.02) at follow-up. CONCLUSION: Supplementation of probiotic L. rhamnosus GR-1 and L. reuteriRC-14 did not enhance the cure of BV among women living with HIV, but may prevent the condition among this population. TRIAL REGISTRATION: NCT00536848.
Authors: Jean M Macklaim; Craig R Cohen; Gilbert Donders; Gregory B Gloor; Janet E Hill; Groesbeck P Parham; Jacques Ravel; Gregory Spear; Janneke van de Wijgert; Gregor Reid Journal: Reprod Sci Date: 2012-05-21 Impact factor: 3.060
Authors: Manjula Gunawardana; Madeline Mullen; Jennifer Yoo; Paul Webster; John A Moss; Marc M Baum Journal: Antimicrob Agents Chemother Date: 2014-02-03 Impact factor: 5.191
Authors: Shweta Malik; Mariya I Petrova; Ingmar J J Claes; Tine L A Verhoeven; Pieter Busschaert; Mario Vaneechoutte; Bart Lievens; Ivo Lambrichts; Roland J Siezen; Jan Balzarini; Jos Vanderleyden; Sarah Lebeer Journal: Appl Environ Microbiol Date: 2013-05-24 Impact factor: 4.792
Authors: Cindy M Liu; Zoe R Packman; Alison G Abraham; David M Serwadda; Fred Nalugoda; Maliha Aziz; Jessica L Prodger; Rupert Kaul; Sarah Kalibbala; Ronald H Gray; Lance B Price; Thomas C Quinn; Aaron Ar Tobian; Steven J Reynolds Journal: Open Forum Infect Dis Date: 2019-07-12 Impact factor: 3.835